

Supplementary Table 1. Clinical characteristics among the control groups: healthy donors, HBV-infected and HCV/HBV-negative LT patients with liver inflammation. All patients were biopsied as clinically indicated.

Patient ID	Control group	Age (years)	Gender (M/F)	IS	AST/ALT (IU/mL)	METAVIR stage	Histopathological diagnosis
P20	Healthy donors (n=10)	30	M	-	28/50	F0	Mild hemosiderosis
P21		30	M	-	21/18	F0	Mild hemosiderosis
P22		53	M	-	28/38	F0	Moderate hemosiderosis
P23		43	F	-	NA	F0	NAD
P24		54	F	-	NA/26	F0	Mild steatosis
P25		46	F	-	12/15	F0	NAD
P26		36	M	-	31/26	F0	Mild steatosis
P27		22	M	-	27/23	F0	Minimal changes
P28		28	M	-	25/33	F0	Mild hemosiderosis
P29		43	F	-	14/8	F0	NAD
P30	HBV (n=8)	27	M	-	231/574	F2	Suggestive of HBV infection
P31		40	M	-	31/44	F1	Suggestive of HBV infection
P32		49	F	-	53/60	F3	Suggestive of HBV infection
P33		37	M	-	48/68	F2	Compatible with HBV
P34		44	M	-	69/70	F3	Suggestive of HBV infection
P35		33	M	-	55/85	F2	Suggestive of HBV infection
P36		48	M	-	93/97	F3	Suggestive of HBV infection
P37		33	M	-	46/61	F1	Suggestive of HBV infection

P38	LT with inflammatory changes (n=10)	69	M	Other	52/73	F0	Steatohepatitis
P39		61	M	FK	11/25	F0	Rejection
P40		54	F	FK	22/20	F0	Unspecific inflammation
P41		31	F	CyS	55/215	F0	Rejection
P42		54	M	CyS	64/168	F1	Rejection
P43		59	M	FK	29/55	F0	Rejection
P44		38	M	FK	213/317	F0	Rejection
P45		69	M	FK	39/39	F0	Autoimmune hepatitis
P46		46	F	Other	43/53	F0	PBC recurrence
P47		67	M	CyS	100/88	F0	Rejection

LT, liver transplant; M/F, male/female; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IS, immunosuppression regimen; CyS, Cyclosporine A; FK, Tacrolimus; Other, mTOR inhibitor; PBC, primary biliary cirrhosis; NAD, nothing abnormal detected.